Alberto Pavan

5PUBLICATIONS
24CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

|Feb 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Antonello Veccia, Ettore D'Argento, Floriana Morgillo

|Oct 17, 2024
Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer.

Andrea Boscolo Bragadin, Paola Del Bianco, Elisabetta Zulato

|May 31, 2022
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.

Alberto Pavan, Alessandra Ferro, Francesco Fortarezza

|Apr 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.

Giulia Pasello, Martina Lorenzi, Lorenzo Calvetti

Pageof 1

Frequent Collaborators

2 joint publications

Giulia Pasello

2 joint publications

PierFranco Conte

2 joint publications

Antonello Veccia

1 joint publications

Andrea Boscolo Bragadin